Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia

World Journal of Surgery

Volumn 27, Issue 9, 2003, Pages 1035-1039

  Ott, Katja ^a   Weber, Wolfgang A ^b   Fink, Ulrich ^a   Helmberger, Hermann ^b   Becker, Karen ^b   Stein, Hubert J ^a   Müller, James ^b   Schwaiger, Markus ^b   Siewert, Jörg Rüdiger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CARDIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG UPTAKE; ESOPHAGUS CARCINOMA; ESOPHAGUS TUMOR; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; METABOLISM; MORTALITY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; BLOOD GLUCOSE; CARDIA; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141653801     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-003-7058-9     Document Type: Article

References (29)

1. Warburg O, The Metabolism of Tumors, London, Constable, 1930
2. Fischman AJ, Alpert NM. FDG-PET in oncology: There's more to it than looking at pictures. J. Nucl. Med. 1993;34:6-11
3. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodesoxyglucose. Eur. J. Nucl. Med. 1996;23:1641-1674
4. Prôuer H, Weber W, Römer W, et al. Evaluation of pulmonary nodules by positron emission tomography using the glucose analogue fluorine-18-fluorodeoxyglucose (FDG). A controlled prospective study in 50 patients. Br. J. Surg. 1998;85:1506-1511
5. Wahl RL, Cody RL, Hutchins G, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770
6. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J. Clin. Oncol. 1998;16:603-609
7. Römer W, Hanauske AR, Ziegeler S, et al. Positron emission tomography in non-Hodgkin lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-4471
8. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J. Nucl. Med. 1993;34:1711-1716
9. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J. Nucl. Med. 1996;37:1438-1444
10. Lai DTM, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch. Surg. 1996; 131:703-707
11. Findlay M, Young H, Cunningham H, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastasis: correlation with tumor response to fluorouracil. J. Clin. Oncol. 1996;14:700-708
12. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 1999;36:31-35
13. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J. Clin. Oncol. 1999;17:3201-3206
14. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82:2227-2234
15. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br. J. Surg. 1998;85:1403-1406
16. McAteer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br. J. Radiol. 1999;72:525-529
17. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J. Thorac. Cardiovasc. Surg. 2000;120:1085-1092
18. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J. Clin. Oncol. 2000;18:3202-3210
19. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Am. J. Roentgenol. 1997;168:417-424
20. Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br. J. Cancer 1998;78:521-527
21. Siewert JR, Stein HJ. Classification of the adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 1998;85:1457-1459
22. DiChiro G, Hatazawa J, Katz DA, et al. Glucose utilisation by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987;165:521-526
23. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation and uptake with prognosis. J. Nucl. Med. 1991;32:686-691
24. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of muscoloskeletal tumors using PET. J. Nucl. Med. 1991;32:1508-1512
25. Fukunga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J. Nucl. Med. 1998;39: 1002-1007
26. Wijnhoven BPL, Siersema PD, Hop WCJ, et al. Adenocarcinomas of the distal esophagus and gastric cardia are one clinical entity. Br. J. Surg. 1999;86:529-535
27. Kalish RJ, Clancy PE, Orringer MB, et al. Clinical, epidemiologic and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 1984;86:461-467
28. Clark GWB, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia. Arch. Surg. 1994;129:609-614
29. Schneider PM, Schweighart P, Stöltzing O et al. (1997) "Molecular evidence that cancer of the gastric cardia is different from Barrett's cancer and related to proximal third gastric cancer" In: Siewart, JR, Roder, JD (editors), 2nd International Gastric Cancer Congress, Book of Abstracts 6:Abstract 0549